GlobeImmune
Blood & Organ Banks · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1450 Infinite Dr, Louisville, Colorado, ...Phone Number
(303) 625-2700Website
www.globeimmune.comRevenue
$6.2 MillionStock Symbol
GBIMIndustry
About GlobeImmune
GlobeImmune is focused on developing Tarmogen product candidates aimed at treating cancer and infectious diseases. Their innovative Tarmogens activate the immune system by stimulating T cells to target and destroy infected or malignant cells, differentiating them from traditional vaccines. The company targets specific antigens associated with oncology and infectious disease indications. Their intended clients include patients suffering from these conditions, as well as healthcare providers involved in cancer and infectious disease treatment.Explore more
GlobeImmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to GlobeImmune
Compare insights from companies similar to GlobeImmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$5.9M
51-200
Private
-
2010
GlobeImmune Tech Stack
A closer look at the technologies used by GlobeImmune
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GlobeImmune
Sign Up For FreeTo access detailed company insights
GlobeImmune is focused on developing Tarmogen product candidates aimed at treating cancer and infectious diseases. Their innovative Tarmogens activate the immune system by stimulating T cells to target and destroy infected or malignant cells, differentiating them from traditional vaccines. The company targets specific antigens associated with oncol... Read More
